Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- COPD Treatments, Smoking Cessation Aids to Show Double-Digit Growth: Fuji-Keizai
November 1, 2010
- Mediscience: FY2010 Business Results Fall Short of Forecasts
November 1, 2010
- IMSUT Objects to Asahi Shimbun News
November 1, 2010
- JMA, JAMS Oppose JSLN's Cholesterol GL for Longevity
November 1, 2010
- Eli Lilly Japan to Target Orthopedic Surgeons in Promoting Forteo
October 25, 2010
- Continued Sales of Ketoprofen Products Should Be Permitted: CDFS
October 25, 2010
- Allermist Improves Ophthalmic Allergic Symptoms: Prof. Kurono
October 25, 2010
- CSO Market to Grow at 14.4% in FY2010 and Onward: MIC Research
October 25, 2010
- Original Itraconazole Product Shows Inter-Lot Differences
October 25, 2010
- 2 Kohdo-iryo Recommended for Use under Health Insurance Programs
October 25, 2010
- Price Settlement Rate 17.9% as of September at NPhA Members
October 25, 2010
- Takeda Licenses Cervical Cancer Vaccine from JHSF
October 25, 2010
- Free Coupons for Cervical, Breast Cancer Exam Used by About 20% of Eligible Women
October 25, 2010
- Gilead's HBV Drug Licensed to GSK in Japan
October 25, 2010
- BIBW 2992 Extends PFS in NSCLC Patients: BI
October 25, 2010
- Risk Classification for 7 APIs Reviewed
October 25, 2010
- CMIC, Fujirebio to Collaborate to Market RENAPRO L-FABP Test
October 25, 2010
- US, EU Submissions for BSI-201 for mTNBC in 2011
October 25, 2010
- Chugai's Alliance with Roche Enters 2nd Phase
October 25, 2010
- Takepron Ranked No. 1 in HP Market: RepTrack Survey
October 25, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…